BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Laharie D, Reffet A, Belleannée G, Chabrun E, Subtil C, Razaire S, Capdepont M, de Lédinghen V. Mucosal healing with methotrexate in Crohn’s disease: a prospective comparative study with azathioprine and infliximab. Aliment Pharmacol Ther. 2011;33:714-721. [PMID: 21235604 DOI: 10.1111/j.1365-2036.2010.04569.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Mantzaris GJ. Thiopurines and Methotrexate Use in IBD Patients in a Biologic Era. Curr Treat Options Gastro 2017;15:84-104. [DOI: 10.1007/s11938-017-0128-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
2 Caprilli R, Latella G, Frieri G. Treatment of inflammatory bowel diseases: to heal the wound or to heal the sick? J Crohns Colitis 2012;6:621-5. [PMID: 22425510 DOI: 10.1016/j.crohns.2012.02.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
3 Therrien A, Chapuy L, Bsat M, Rubio M, Bernard G, Arslanian E, Orlicka K, Weber A, Panzini BP, Dorais J, Bernard EJ, Soucy G, Bouin M, Sarfati M. Recruitment of activated neutrophils correlates with disease severity in adult Crohn's disease. Clin Exp Immunol 2019;195:251-64. [PMID: 30347439 DOI: 10.1111/cei.13226] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
4 Agrawal G, Clancy A, Huynh R, Borody T. Profound remission in Crohn's disease requiring no further treatment for 3-23 years: a case series. Gut Pathog. 2020;12:16. [PMID: 32308741 DOI: 10.1186/s13099-020-00355-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
5 Rouiller-Braunschweig C, Fournier N, Pittet V, Dudler J, Michetti P. Efficacy, Safety and Mucosal Healing of Methotrexate in a Large Longitudinal Cohort of Inflammatory Bowel Disease Patients. Digestion 2017;96:220-7. [PMID: 29065423 DOI: 10.1159/000482007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
6 Amaro F, Chiarelli F. Growth and Puberty in Children with Inflammatory Bowel Diseases. Biomedicines 2020;8:E458. [PMID: 33138015 DOI: 10.3390/biomedicines8110458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Rogler G, Vavricka S, Schoepfer A, Lakatos PL. Mucosal healing and deep remission: What does it mean? World J Gastroenterol 2013; 19(43): 7552-7560 [PMID: 24282345 DOI: 10.3748/wjg.v19.i43.7552] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
8 Reenaers C, Belaiche J, Louis E. Impact of medical therapies on inflammatory bowel disease complication rate. World J Gastroenterol 2012; 18(29): 3823-3827 [PMID: 22876033 DOI: 10.3748/wjg.v18.i29.3823] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
9 Durko L, Stasikowska-Kanicka OA, Wagrowska-Danilewicz M, Danilewicz M, Małecka-Panas EI. An analysis of the correlation of clinical, endoscopic and histological classifications in Crohn's disease. Prz Gastroenterol 2013;8:377-82. [PMID: 24868287 DOI: 10.5114/pg.2013.39921] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Miheller P, Mandel MD, Mullner K, Lakatos PL. Clinical aspects of mucosal healing in inflammatory bowel diseases: what is it and what is the real value for the everyday practice? Expert Rev Clin Immunol 2013;9:871-82. [PMID: 24070050 DOI: 10.1586/1744666X.2013.824675] [Reference Citation Analysis]
11 Nielsen OH, Steenholdt C, Juhl CB, Rogler G. Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. EClinicalMedicine 2020;20:100271. [PMID: 32300735 DOI: 10.1016/j.eclinm.2020.100271] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
12 Antunes O, Filippi J, Hébuterne X, Peyrin-Biroulet L. Treatment algorithms in Crohn’s - up, down or something else? Best Pract Res Clin Gastroenterol. 2014;28:473-483. [PMID: 24913386 DOI: 10.1016/j.bpg.2014.05.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
13 Moy MP, Sauk J, Gee MS. The Role of MR Enterography in Assessing Crohn's Disease Activity and Treatment Response. Gastroenterol Res Pract 2016;2016:8168695. [PMID: 26819611 DOI: 10.1155/2016/8168695] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
14 Reisdorf WC, Xie Q, Zeng X, Xie W, Rajpal N, Hoang B, Burgert ME, Kumar V, Hurle MR, Rajpal DK, O'Donnell S, MacDonald TT, Vossenkämper A, Wang L, Reilly M, Votta BJ, Sanchez Y, Agarwal P. Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease. PLoS One 2019;14:e0215033. [PMID: 31002701 DOI: 10.1371/journal.pone.0215033] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
15 Allen PB, Peyrin-Biroulet L. Immunomodulators for the treatment of Crohn's disease in adults: optimal use and prospects for future drug treatments. Expert Rev Clin Immunol. 2016;12:741-749. [PMID: 26900725 DOI: 10.1586/1744666x.2016.1154789] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Hakim GD, Soyturk M, Unlu M, Ataca P, Karaman M, Sagol O, Borekci E, Yilmaz O. Mucosal healing effect of nilotinib in indomethacin-induced enterocolitis: A rat model. World J Gastroenterol 2015; 21(44): 12576-12585 [PMID: 26640333 DOI: 10.3748/wjg.v21.i44.12576] [Reference Citation Analysis]
17 Beppu T, Ono Y, Matsui T, Hirai F, Yano Y, Takatsu N, Ninomiya K, Tsurumi K, Sato Y, Takahashi H, Ookado Y, Koga A, Kinjo K, Nagahama T, Hisabe T, Takaki Y, Yao K. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease: Ileal mucosal healing by IFX in CD. Digestive Endoscopy 2015;27:73-81. [DOI: 10.1111/den.12313] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
18 Fabian O, Hradsky O, Potuznikova K, Kalfusova A, Krskova L, Hornofova L, Zamecnik J, Bronsky J. Low predictive value of histopathological scoring system for complications development in children with Crohn’s disease. Pathology - Research and Practice 2017;213:353-8. [DOI: 10.1016/j.prp.2017.01.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
19 McDonald JW, Wang Y, Tsoulis DJ, MacDonald JK, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev. 2014;CD003459. [PMID: 25099640 DOI: 10.1002/14651858.cd003459.pub4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
20 Cintolo M, Costantino G, Pallio S, Fries W. Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. World J Gastrointest Pathophysiol 2016; 7(1): 1-16 [PMID: 26909224 DOI: 10.4291/wjgp.v7.i1.1] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
21 Mazzuoli S, Guglielmi FW, Antonelli E, Salemme M, Bassotti G, Villanacci V. Definition and evaluation of mucosal healing in clinical practice. Dig Liver Dis. 2013;45:969-977. [PMID: 23932331 DOI: 10.1016/j.dld.2013.06.010] [Cited by in Crossref: 73] [Cited by in F6Publishing: 58] [Article Influence: 8.1] [Reference Citation Analysis]
22 McDonald JW, Tsoulis DJ, Macdonald JK, Feagan BG. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev. 2012;12:CD003459. [PMID: 23235598 DOI: 10.1002/14651858.cd003459.pub3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
23 Nejati S, Wang J, Heredia-Rivera U, Sedaghat S, Woodhouse I, Johnson JS, Verma M, Rahimi R. Small intestinal sampling capsule for inflammatory bowel disease type detection and management. Lab Chip 2021;22:57-70. [PMID: 34826326 DOI: 10.1039/d1lc00451d] [Reference Citation Analysis]
24 Bertani L, Fornai M, Fornili M, Antonioli L, Benvenuti L, Tapete G, Baiano Svizzero G, Ceccarelli L, Mumolo MG, Baglietto L, de Bortoli N, Bellini M, Marchi S, Costa F, Blandizzi C. Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. Aliment Pharmacol Ther 2020;52:284-91. [PMID: 32506635 DOI: 10.1111/apt.15870] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
25 Wang X, Wang G, Shang J, Pan H, Zhang XA, Zhou F. Immunosuppressive therapies adversely affect blood biochemical parameters in patients with inflammatory bowel disease: a meta-analysis. J Int Med Res 2019;47:3534-49. [PMID: 31364448 DOI: 10.1177/0300060519864800] [Reference Citation Analysis]
26 Klenske E, Bojarski C, Waldner M, Rath T, Neurath MF, Atreya R. Targeting mucosal healing in Crohn's disease: what the clinician needs to know. Therap Adv Gastroenterol 2019;12:1756284819856865. [PMID: 31236140 DOI: 10.1177/1756284819856865] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
27 Novak G, Parker CE, Pai RK, MacDonald JK, Feagan BG, Sandborn WJ, D'Haens G, Jairath V, Khanna R. Histologic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev 2017;7:CD012351. [PMID: 28731502 DOI: 10.1002/14651858.CD012351.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
28 de Paula-Silva M, da Rocha GHO, Broering MF, Queiroz ML, Sandri S, Loiola RA, Oliani SM, Vieira A, Perretti M, Farsky SHP. Formyl Peptide Receptors and Annexin A1: Complementary Mechanisms to Infliximab in Murine Experimental Colitis and Crohn's Disease. Front Immunol 2021;12:714138. [PMID: 34603288 DOI: 10.3389/fimmu.2021.714138] [Reference Citation Analysis]
29 González-lama Y, Taxonera C, López-sanromán A, Pérez-calle JL, Bermejo F, Pajares R, Mcnicholl AG, Opio V, Mendoza JL, López P, Algaba A, Estelles J, Barbero A, Mendoza J, Maté J, Gisbert JP. Methotrexate in inflammatory bowel disease: a multicenter retrospective study focused on long-term efficacy and safety. The Madrid experience. European Journal of Gastroenterology & Hepatology 2012;24:1086-91. [DOI: 10.1097/meg.0b013e3283556db5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
30 Villanacci V, Antonelli E, Geboes K, Casella G, Bassotti G. Histological healing in inflammatory bowel disease: A still unfulfilled promise. World J Gastroenterol 2013; 19(7): 968-978 [PMID: 23467585 DOI: 10.3748/wjg.v19.i7.968] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 55] [Article Influence: 6.3] [Reference Citation Analysis]
31 Cucchiara S, D'Arcangelo G, Isoldi S, Aloi M, Stronati L. Mucosal healing in Crohn's disease: new insights. Expert Rev Gastroenterol Hepatol. 2020;14:335-345. [PMID: 32315209 DOI: 10.1080/17474124.2020.1759416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
32 Latella G, Papi C. Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol 2012; 18(29): 3790-3799 [PMID: 22876029 DOI: 10.3748/wjg.v18.i29.3790] [Cited by in CrossRef: 71] [Cited by in F6Publishing: 62] [Article Influence: 7.1] [Reference Citation Analysis]
33 De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal Healing in Crohnʼs Disease: A Systematic Review. Inflammatory Bowel Diseases 2013;19:429-44. [DOI: 10.1002/ibd.22977] [Cited by in Crossref: 101] [Cited by in F6Publishing: 88] [Article Influence: 11.2] [Reference Citation Analysis]
34 Gomollón F, Rubio S, Charro M, García-López S, Muñoz F, Gisbert JP, Domènech E; En Representación de GETECCU. [Reccomendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of methotrexate in inflammatory bowel disease]. Gastroenterol Hepatol 2015;38:24-30. [PMID: 25454602 DOI: 10.1016/j.gastrohep.2014.10.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
35 Shah J, Thakur ML, Dutta U. Mucosal healing in inflammatory bowel disease: Expanding horizon. Indian J Gastroenterol 2019;38:98-109. [PMID: 31037509 DOI: 10.1007/s12664-019-00950-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
36 Gong W, Guo K, Zheng T, Fang M, Xie H, Li W, Hong Z, Ren H, Gu G, Wang G, Wu X, Wang Z, Ren J, Li J. Correlation between endoscopic and histological validated scoring indices in Crohn’s disease. Digestive and Liver Disease 2019;51:812-7. [DOI: 10.1016/j.dld.2019.01.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
37 Christensen B, Erlich J, Gibson PR, Turner JR, Hart J, Rubin DT. Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn's Disease than Endoscopic Healing. Clin Gastroenterol Hepatol 2020; 18: 2518-2525. e1. [PMID: 31812654 DOI: 10.1016/j.cgh.2019.11.056] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
38 Hojsak I, Mišak Z, Jadrešin O, Močić Pavić A, Kolaček S. Methotrexate is an efficient therapeutic alternative in children with thiopurine-resistant Crohn's disease. Scand J Gastroenterol 2015;50:1208-13. [PMID: 25877164 DOI: 10.3109/00365521.2015.1031166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
39 Cassinotti A, Batticciotto A, Parravicini M, Lombardo M, Radice P, Cortelezzi CC, Segato S, Zanzi F, Cappelli A, Segato S. Evidence-based efficacy of methotrexate in adult Crohn's disease in different intestinal and extraintestinal indications. Therap Adv Gastroenterol 2022;15:17562848221085889. [PMID: 35340755 DOI: 10.1177/17562848221085889] [Reference Citation Analysis]
40 Armuzzi A, Van Assche G, Reinisch W, de Chambrun GP, Griffiths A, Sladek M, Preiss JC, Lukas M, D'haens G. Results of the 2nd scientific workshop of the ECCO (IV): Therapeutic strategies to enhance intestinal healing in inflammatory bowel disease. Journal of Crohn's and Colitis 2012;6:492-502. [DOI: 10.1016/j.crohns.2011.12.016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
41 Christensen B, Rubin DT. Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice. Curr Gastroenterol Rep 2016;18. [DOI: 10.1007/s11894-015-0477-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
42 Mao R, Guo J, Luber R, Chen BL, He Y, Zeng ZR, Ben-Horin S, Sparrow MP, Roblin X, Chen MH. 6-Thioguanine Nucleotide Levels Are Associated With Mucosal Healing in Patients With Crohn's Disease. Inflamm Bowel Dis 2018;24:2621-7. [PMID: 29788262 DOI: 10.1093/ibd/izy173] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
43 Patel V, Wang Y, MacDonald JK, McDonald JW, Chande N. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2014;(8):CD006884. [PMID: 25157445 DOI: 10.1002/14651858.cd006884.pub3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
44 Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H. Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives. World J Gastroenterol 2015; 21(1): 21-46 [PMID: 25574078 DOI: 10.3748/wjg.v21.i1.21] [Cited by in CrossRef: 91] [Cited by in F6Publishing: 76] [Article Influence: 13.0] [Reference Citation Analysis]
45 Flamant M, Roblin X. Inflammatory bowel disease: towards a personalized medicine. Therap Adv Gastroenterol 2018;11:1756283X17745029. [PMID: 29383027 DOI: 10.1177/1756283X17745029] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
46 Moy MP, Kaplan JL, Moran CJ, Winter HS, Gee MS. MR Enterographic Findings as Biomarkers of Mucosal Healing in Young Patients With Crohn Disease. AJR Am J Roentgenol 2016;207:896-902. [PMID: 27351067 DOI: 10.2214/AJR.16.16079] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
47 Dilillo D, Guazzarotti L, Galli E, Zuccotti GV. Mechanisms and management of growth impairment in children affected by inflammatory bowel disease. Expert Rev Endocrinol Metab 2013;8:289-99. [PMID: 30780818 DOI: 10.1586/eem.13.12] [Reference Citation Analysis]
48 Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology. 2015; 148:37-51.e1. [PMID: 25127678 DOI: 10.1053/j.gastro.2014.08.003] [Cited by in Crossref: 142] [Cited by in F6Publishing: 124] [Article Influence: 17.8] [Reference Citation Analysis]
49 Vaughn BP, Shah S, Cheifetz AS. The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol 2014;12:103-17. [PMID: 24395615 DOI: 10.1007/s11938-013-0008-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
50 Narula N, Peyrin-biroulet L, Colombel J. Combination Therapy With Methotrexate in Inflammatory Bowel Disease: Time to COMMIT? Gastroenterology 2014;146:608-11. [DOI: 10.1053/j.gastro.2014.01.040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
51 Renna S, Orlando A, Cottone M. Comparing medical treatments for Crohn's disease. J Comp Eff Res 2013;2:135-49. [PMID: 24236556 DOI: 10.2217/cer.13.2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
52 Ruemmele F, Veres G, Kolho K, Griffiths A, Levine A, Escher J, Amil Dias J, Barabino A, Braegger C, Bronsky J, Buderus S, Martín-de-carpi J, De Ridder L, Fagerberg U, Hugot J, Kierkus J, Kolacek S, Koletzko S, Lionetti P, Miele E, Navas López V, Paerregaard A, Russell R, Serban D, Shaoul R, Van Rheenen P, Veereman G, Weiss B, Wilson D, Dignass A, Eliakim A, Winter H, Turner D. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. Journal of Crohn's and Colitis 2014;8:1179-207. [DOI: 10.1016/j.crohns.2014.04.005] [Cited by in Crossref: 580] [Cited by in F6Publishing: 470] [Article Influence: 72.5] [Reference Citation Analysis]
53 Chen JM, He LW, Yan T, Guo XF, Hu PJ, Peng JS, Cheng WJ, Li LL, He Q. Oral exclusive enteral nutrition induces mucosal and transmural healing in patients with Crohn's disease. Gastroenterol Rep (Oxf). 2019;7:176-184. [PMID: 31217981 DOI: 10.1093/gastro/goy050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Shah SC, Colombel J, Sands BE, Narula N. Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2016;14:1245-1255.e8. [DOI: 10.1016/j.cgh.2016.01.015] [Cited by in Crossref: 132] [Cited by in F6Publishing: 122] [Article Influence: 22.0] [Reference Citation Analysis]
55 Rutgeerts P, Gasink C, Chan D, Lang Y, Pollack P, Colombel JF, Wolf DC, Jacobstein D, Johanns J, Szapary P, Adedokun OJ, Feagan BG, Sandborn WJ. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. Gastroenterology 2018;155:1045-58. [PMID: 29909019 DOI: 10.1053/j.gastro.2018.06.035] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 16.3] [Reference Citation Analysis]
56 Mojtahed A, Khanna R, Sandborn WJ, D'Haens GR, Feagan BG, Shackelton LM, Baker KA, Dubcenco E, Valasek MA, Geboes K, Levesque BG. Assessment of histologic disease activity in Crohn's disease: a systematic review. Inflamm Bowel Dis. 2014;20:2092-2103. [PMID: 25137418 DOI: 10.1097/mib.0000000000000155] [Cited by in Crossref: 31] [Cited by in F6Publishing: 7] [Article Influence: 4.4] [Reference Citation Analysis]
57 Moreau J, Mas E. Drug resistance in inflammatory bowel diseases. Curr Opin Pharmacol. 2015;25:56-61. [PMID: 26645664 DOI: 10.1016/j.coph.2015.11.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
58 Huang Z, Chao K, Li M, Zhi M, Tang J, Hu P, Gao X. Methotrexate for Refractory Crohn's Disease Compared with Thiopurines: A Retrospective Non-head-to-head Controlled Study. Inflamm Bowel Dis 2017;23:440-7. [PMID: 28129286 DOI: 10.1097/MIB.0000000000001022] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]